Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
A composition and method for treating excess cyanide and hydrogen sulfide comprising administering a cobinamide. Further a method for determining extent of binding by an agent to an extracellular matrix.
1. A compound having the formula:
or pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising the compound of claim 1 .
3. A composition comprising the compound of claim 1 and nitrite ion.
4. The composition of claim 3 wherein a molar ratio of the compound of claim 1 to the nitrite ion is between 1:1 and 1:2.
5. A method for treating sulfide poisoning or cyanide exposure in a subject comprising administering a therapeutically effective amount of a cobinamide to the subject, wherein the cobinamide is aquohydroxocobinamide, dinitrocobinamide or sulfitocobinamide.
6. The method of claim 5 wherein the subject is a human.
7. The method of claim 5 wherein the cobinamide is dinitrocobinamide.
8. The method of claim 5 wherein the cobinamide is administered intravenously.
9. The method of claim 5 wherein the cobinamide is administered intramuscularly.
10. The method of claim 5 wherein the cobinamide is administered at a dose of between 2 mg/kg and 25 mg/kg.
11. The method of claim 10 wherein the dose is between 2 mg/kg and 17 mg/kg.
12. The method of claim 10 wherein the dose is between 2 mg/kg and 15 mg/kg.
13. The method of claim 10 wherein the dose is between 15 mg/kg and 17 mg/kg.
14. A method of determining an extent of binding of an agent to extracellular matrix, the method comprising:
providing a sample of mammalian extracellular matrix;
contacting the sample with a solution comprising a known concentration of the agent;
allowing binding to occur; and
determining a second concentration of the agent remaining in the solution.
15. The method of claim 14 wherein the extracellular matrix is from muscle tissue.
16. The method of claim 14 wherein the extracellular matrix comprises decellularized skeletal muscle extracellular matrix.
17. The method of claim 14 wherein the agent is a cobinamide.
18. The method of claim 14 wherein determining a second concentration of the agent comprises a spectrophotometric method.
19. The method of claim 5 , wherein the cobinamide is dinitrocobinamide, the dinitrocobinamide is administered intramuscularly, the dinitrocobinamide is administered as a pharmaceutical composition comprising the dinitrocobinamide and nitrite ions, and the molar ratio of the dinitrocobinamide to the nitrite ions is between 1:1 and 1:2.